<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017316</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068677</org_study_id>
    <secondary_id>UTHSC-IDD-99-27</secondary_id>
    <secondary_id>SACI-IDD-99-27</secondary_id>
    <secondary_id>NCI-66</secondary_id>
    <nct_id>NCT00017316</nct_id>
  </id_info>
  <brief_title>Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Phase II, Pharmacologic and Biologic Study of Escalating Doses of Thalidomide (NSC #66847) Administered Orally Once a Day in Combination With a Fixed Dose of SU5416 (NSC #696819) in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of combining thalidomide and SU5416 in treating&#xD;
      patients who have metastatic melanoma. Thalidomide combined with SU5416 may stop the growth&#xD;
      of metastatic melanoma by stopping blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of thalidomide and SU5416 in patients with metastatic melanoma.&#xD;
&#xD;
      II. Determine the quantitative and qualitative toxic effects of this regimen in these&#xD;
      patients.&#xD;
&#xD;
      III. Evaluate the pharmacokinetics of this regimen in these patients. IV. Determine the&#xD;
      complete and partial responses and response duration in patients treated with this regimen.&#xD;
&#xD;
      V. Assess disease-free survival at 6 months of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1&#xD;
      day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaxanib</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic melanoma&#xD;
&#xD;
          -  Bidimensionally measurable disease by MRI, CT scan, or chest x-ray&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8.5 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT/PTT normal&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncompensated coronary artery disease by electrocardiogram or physical exam&#xD;
&#xD;
          -  No myocardial infarction or severe or unstable angina within the past 6 months&#xD;
&#xD;
          -  No deep venous thrombosis within the past 3 months&#xD;
&#xD;
          -  No arterial thrombosis within the past 6 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary embolism within the past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No medical, psychological, or social problem that would preclude study participation&#xD;
&#xD;
          -  No history of gastrointestinal disorder that would interfere with absorption or&#xD;
             swallowing of study medication&#xD;
&#xD;
          -  No emotional disorder or substance abuse&#xD;
&#xD;
          -  No diabetes mellitus with severe peripheral vascular disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of effective contraception for 4 weeks before,&#xD;
             during, and for 4 weeks after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No more than 1 prior biologic regimen&#xD;
&#xD;
          -  No concurrent biologic response modifiers&#xD;
&#xD;
          -  No concurrent hematopoietic growth factor support&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent cytotoxic agents&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy except megestrol acetate for appetite&#xD;
             stimulation&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior large field radiotherapy to more than 20% total bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 14 days since major surgery&#xD;
&#xD;
          -  No prior major upper gastrointestinal surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric K. Rowinsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>June 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

